DR. REDDY'S

Dr. Reddy's Laboratories Ltd.
8-2-337, Road No.3, Banjara Hills
Hyderabad 500 034, A.P., India.
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
www.drreddys.com

July 21, 2011

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai - 400 001
Fax Nos.: 022-22723121 / 22723719 /
22722037 / 22722039

Scrip Code : 500124

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code :* DRREDDY-*EQ / N1

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on **"Dr. Reddy's announces filing of Annual Report on Form 20-F".**

Kindly arrange to disseminate and display the same on your Notice Board for the purpose of information.

With regards,

Sandeep Poddar
Company Secretary

Encl: as above

CC : New York Stock Exchange Inc.

Press Release

DR. REDDY'S

Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F

Hyderabad, India, July 21, 2011: Dr. Reddy's Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2011 was filed with the United States Securities and Exchange Commission on July 20, 2011.

The Annual Report on Form 20-F is also available on Dr. Reddy's website, **www.drreddys.com** and can be accessed by selecting 'SEC filings' under the 'Investors' Section. ADS holders may also obtain a hard copy of the Annual Report on Form 20-F at no cost, by sending a written request to the Company's registered office or by sending an e-mail to **shares@drreddys.com**.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's

Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We fulfill our purpose of providing affordable and innovative medicines through three core businesses: Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia.
www.drreddys.com

For Dr. REDDY'S LABORATORIES LTD.

SANDEEP PODDAR
COMPANY SECRETARY

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com / +91-40-66834297
Raghavender R at raghavenderr@drreddys.com / +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com / 908-203-4931

Media:
S Rajan at rajans@drreddys.com / +91-40- 49002445